Tarlatamab for Small Cell Lung Cancer — Talking To Patients About The Risks & Benefits

Platinum-resistant small cell lung cancer (SCLC) presents its own unique challenges for patients and physicians alike. Median survival in this group is usually around 2-8 months. Treatment options are limited, toxic, and overall response rates are low. However, a new bispecific antibody, tarlatamab, is changing the landscape in the management of platinum resistant SCLC.

“This is a new form of immunotherapy that actually links the immune cell to the tumor cell and leads to tumor cell lysis,” Dr. Charles Rudin, a thoracic oncologist at Memorial Sloan Kettering Cancer Center, tells SurvivorNet Connect.

For certain patients, research indicates a lot of potential for the drug — but the risks vs. benefits must be considered on a case by case basis.

Mechanism of Action

Tarlatamab is designed to redirect endogenous T cells toward tumor cells by simultaneously binding CD3 on T lymphocytes and DLL3 on tumor cells. DLL3 is an inhibitory notch ligand that is highly expressed on the surface of small-cell lung cancer cells but largely absent from normal adult tissues, making it an attractive therapeutic target. By physically linking T cells to DLL3-expressing tumor cells, tarlatamab induces T-cell activation, cytokine release, and targeted cytotoxicity independent of antigen presentation or MHC expression.

Unlike antibody-drug conjugates or cytotoxic chemotherapy, the antitumor activity of tarlatamab depends on immune engagement rather than direct tumor cell poisoning. As a result, both its efficacy and toxicity profile are driven by immune activation rather than dose-dependent cytopenias or cumulative organ injury.

Safety and Risks

When discussing the potential risks of tarlatamab, it is important to mention that patients who are ultimately treated will need close monitoring in the hospital for at least the first 2 doses to monitor for CRS and ICANS. CRS is the most common and serious toxicity that can affect up to half of all patients on the drug. Still, data indicate that the approach can work in an outpatient setting.

“There’s ongoing trials actually showing that we can now do it in the outpatient setting with close monitoring after those first two infusions,” Dr. Rudin says.

Key toxicities and safety considerations are tied to its immune-engaging mechanism and include:

• Cytokine Release Syndrome (CRS): This is the most common serious toxicity. It typically occurs early (after first or second dose), and is usually grade 1-2. It can be more severe in certain cases. CR is managed with supportive care (antipyretics, IV fluids, corticosteroids where indicated).
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): This is a less common but important neurotoxicity which can manifest with confusion, aphasia, tremor or other neurologic symptoms. Higher severity risk may correlate with higher exposures.

Other adverse events might include fatigue, pyrexia, decreased appetite, dysgeusia, nausea, anemia, neutropenia, constipation, and musculoskeletal pain.

Some real-world data suggest that CRS and neurotoxicities may be more frequent/severe outside of tightly controlled clinical trial settings (e.g., patients with brain metastases).

Because of these risks, hospital monitoring is needed for initial doses and baseline neurologic evaluation and close observation are used during early cycles.

Clinical Effectiveness

Clinical development has focused on patients with ES-SCLC who have progressed after platinum-based chemotherapy. In the phase II DeLLphi-301 study, tarlatamab demonstrated objective response rates on the order of 40%, with a subset of patients achieving durable responses lasting close to a year. These response rates are notable in a population where historical second- or third-line therapies typically yield response rates below 20% with limited durability.

More recently, phase III data from DeLLphi-304 comparing tarlatamab with standard chemotherapy in the second-line setting showed a statistically and clinically meaningful overall survival advantage.

• Median overall survival favored tarlatamab by several months, with a relative reduction in the risk of death of approximately 40%.
• Importantly, survival benefit was accompanied by improvements in disease-related symptoms such as dyspnea and cough, suggesting that tumor control translated into functional benefit for patients.

While not all patients respond, those who do can experience disease control that meaningfully exceeds what has historically been achievable in this setting. This has repositioned tarlatamab as a legitimate disease-modifying therapy rather than purely palliative chemotherapy.

Dr. Rudin explains, “this new therapy offers is an improvement in overall survival, which at the median is over a year at about 13.6 months.

Discussing Tradeoffs With Patients

When discussing tarlatamab with patients, it is helpful to frame the therapy as offering a different type of tradeoff than chemotherapy rather than simply “more treatment.” Patients should understand that tarlatamab offers a real chance of tumor response and longer survival compared with standard second-line options, but that benefit is not guaranteed and occurs in a subset rather than the majority of patients.

A useful framing is to explain that the drug activates the immune system against the cancer, which can lead to early inflammatory side effects that sometimes require hospitalization, particularly during the first few doses. Emphasize that these risks are highest early, are closely monitored, and are usually manageable, but they are not trivial and require careful consideration.

Patients should also be counseled that if they do respond, responses can be durable and accompanied by symptom improvement, potentially translating into better quality of life than ongoing chemotherapy. Conversely, for patients who do not respond, the early toxicity burden may occur without long-term benefit, making patient selection and goal alignment critical.

In practice, the decision to proceed with tarlatamab should be guided by performance status, neurologic baseline, social support, and patient priorities. For patients motivated by life prolongation and willing to accept early risk and monitoring, tarlatamab represents one of the most meaningful advances in relapsed SCLC. For patients prioritizing minimal medicalization or those with limited reserve, the balance may favor more conservative approaches.

“There’s traditionally been a lot of nihilism, quite honestly, about this disease. Whether it’s even worth offering therapy for recurrent disease as opposed to just offering supportive care … but at the same time, if they have treatment options that can offer better quality of life and improve survival, we want them to get that option,” Dr. Rudin explains.